Viyash Scientific Limited has reported its strongest quarter in company history, with Q4 FY26 EBITDA surpassing ₹200 crore. Driven by successful operational integration and synergy realization, the company achieved a robust 13.8% increase in annual revenue to ₹34,203 million for FY26. Profit after tax saw a significant annual surge of 1324% to ₹2,246 million, as the company enters FY27 with a deleveraged balance sheet and a focus on long-term value creation.
Record Financial Performance
For the quarter ended March 31, 2026, Viyash Scientific achieved a standout performance with revenues of ₹9,200 million, marking a 19.1% growth compared to the previous year. The company’s EBITDA reached ₹2,001 million, representing a 63.8% increase. On an annual basis, the company sustained this momentum, closing FY26 with a total revenue of ₹34,203 million and an annual EBITDA of ₹7,025 million, up 59.6% year-over-year.
Operational Highlights and Strategic Outlook
The company attributed its success to the seamless integration of facilities and corporate functions into a single unified platform. This strategy has improved operating leverage and fortified the firm against global disruptions. Commenting on the results, Dr. Hari Babu Bodepudi, Managing Director and Group CEO, noted that the merger synergies are now being reflected in the financial performance, contributing to a significantly deleveraged balance sheet with a Net Debt/EBITDA ratio of 0.2x.
Future Growth Strategy
As the company transitions into FY27, the management remains focused on its product pipeline and identified growth roadmap. Viyash Scientific is actively evaluating inorganic opportunities to further expand its platform. With its portfolio spanning formulations, APIs, and CDMO services for human and animal health, the company remains positioned to drive sustainable growth and enhance long-term value for its stakeholders.
Source: BSE
